Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan nelarabine Coverage & Prior …
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 64.0

    Arranon (nelarabine) coverage

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 64.0 alerts

    Get alerted when Policy MBP 64.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for Arranon (nelarabine) across Geisinger Health Plan lines of business including Commercial, Medicare, CHIP, and Medicaid. Applies to providers requesting coverage for nelarabine.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyArranon (nelarabine) coverage
    Policy CodePolicy MBP 64.0
    Change TypeNo material change
    Effective Date
    Last ReviewAug 29, 2024
    Next Review Date
    Key ActionObtain prior authorization from the Medical Director or designee and provide documentation of diagnosis and prior therapy failures.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    T-ALL / T-LBLindications listed as covered
    >=2required prior chemotherapy regimens failed/relapsed
    Prior Authorizationrequires PA
    12 moinitial authorization duration (max)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2024-08-29
    last revision listed
    2025-12-31MA UM approvals through

    Coverage Criteria for Arranon (nelarabine)

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Primary Diagnosis: Physician provided documentation of a diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    Prior Therapy Failure: Physician provided documentation of failure to respond to, or relapse following treatment with a minimum of 2 chemotherapy regimens>=2 regimens
    Brand vs Generic (when applicable): If a brand drug is requested when a therapeutically equivalent generic exists, provide medical record documentation of therapeutic failure on, or intolerance to, the generic formulary agent(s), or documentation of failure/intolerance/contraindication to the inactive ingredients of the generic formulary agent(s)

    Applies when brand is requested

    Eligibility and contract-specific benefit limitations and exclusions may apply. Coverage statements contained in the member's line-of-business benefit document take precedence and supersede this policy when there is a conflict.

    Arranon (nelarabine) will no longer be covered if the patient experiences treatment-related toxicity or clinical worsening of disease. For Medicaid (GHP Family) members, requests that do not meet the PARP criteria will be evaluated on a case-by-case basis.

    Initial Authorization Criteria

    Initial Therapy — explicit initial authorization criteria

    Initial authorization criteria

    Diagnosis: Documentation of T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)

    Physician-provided documentation required

    Prior Regimens: Documentation of failure to respond to, or relapse following, at least 2 chemotherapy regimens>=2

    Physician-provided documentation required

    Continuation / Renewal Criteria

    Continuation Therapy — criteria for subsequent approvals

    Subsequent approvals

    Continuation Approval: Subsequent approvals are for an additional 12 months or less and require medical record documentation of continued disease improvement or lack of disease progression12 months

    Medication will no longer be covered if patient experiences toxicity or worsening of disease

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required by Medical Director or designee

    Prior authorization is required for Arranon (nelarabine) and must be obtained from the Medical Director or their designee before coverage will be considered.

    Prior Authorization

    PA governance and MA UM Committee approvals recorded

    Prior authorization requirements in this policy are governed by the policy document and the policy has MA UM Committee approval dates recorded; specific operational PA instructions are not detailed in the cited sections.

    Documentation Required

    Provide documentation when requesting brand over generic

    Step Therapy / Brand-Over-Generic Requirements

    RequirementDocumentation needed
    Brand requested when therapeutically equivalent generic exists
    Medical record documentation of therapeutic failure on the generic formulary agent(s)
    OR medical record documentation of intolerance to the generic formulary agent(s)
    OR medical record documentation of therapeutic failure on, intolerance to, or contraindication to the inactive ingredients of the generic formulary agent(s)

    Background on Nelarabine

    Nelarabine is a prodrug that is metabolized to ara-GTP, which accumulates in leukemic blasts, incorporates into DNA, inhibits DNA synthesis, and leads to cell death. The policy focuses on nelarabine use in T-cell malignancies (T-ALL and T-LBL) following failure of prior chemotherapy regimens.

    Definitions

    Medical Necessity (Medically Necessary)
    DefinitionMedical Necessity or Medically Necessary: Covered Services rendered by a Health Care Provider that the Plan determines are appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury; provided for the diagnosis and direct care and treatment of the Member's condition; in accordance with current standards of good medical treatment practiced by the general medical community; not primarily for the convenience of the Member or the Member's Health Care Provider; and the most appropriate source or level of service that can safely be provided to the Member.
    Applicability to hospitalizationWhen applied to hospitalization, the Member must require acute care as an inpatient due to the nature of the services or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.
    AppropriatenessServices must be appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury.
    Standards of careServices must be in accordance with current standards of good medical treatment practiced by the general medical community.
    Convenience restriction

    Revision and Review History

    2024-08-29RevisionLatest

    Revised: LOB table and taglines added (document lists 8/29/24 as a revision).

    2023-12-31Revision

    References added to the policy document.

    2023-09-12Revision
    Policy Summary
    PayerGeisinger Health Plan
    PolicyArranon (nelarabine) coverage
    Policy CodePolicy MBP 64.0
    Change TypeNo material change
    Effective Date
    Last ReviewAug 29, 2024
    Next Review Date
    Key ActionObtain prior authorization from the Medical Director or designee and provide documentation of diagnosis and prior therapy failures.
    SourceLink
    On This Page
    Coverage Criteria for Arranon (nelarabine)Initial Authorization CriteriaContinuation / Renewal CriteriaProvider Actions, Prior Authorization, and DocumentationStep Therapy / Brand-Over-Generic RequirementsBackground on NelarabineDefinitionsRevision and Review History

    When a brand product is requested while a therapeutically equivalent generic exists, submit medical record documentation showing therapeutic failure of, or intolerance to, the generic formulary agent(s) or intolerance/contraindication to the generic's inactive ingredients.

    • Documentation of therapeutic failure on the generic formulary agent(s) OR
    • Documentation of intolerance to the generic agent(s) OR
    • Documentation of intolerance to or contraindication to the inactive ingredients of the generic agent(s)
    Step Therapy

    No step therapy rules specified

    No step therapy (step edits) rules are specified in the cited sections of this policy.

    Documentation Required

    Required physician documentation of diagnosis and prior regimen failures

    Provide physician-supplied medical record documentation of the diagnosis (T-ALL or T-LBL) and documentation that the patient failed to respond to, or relapsed following, at least two chemotherapy regimens when requesting authorization.

    • Physician documentation of T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    • Documentation of failure to respond to, or relapse following, a minimum of 2 chemotherapy regimens
    Note

    Reference policy revision and review history for compliance

    The policy includes a revision and review history (devised and multiple revision dates) that should be referenced for administrative compliance and recordkeeping.

    • Devised: 10/8/08; multiple revisions listed including 2/2012, 3/24/15, 9/16/22, 9/12/23, 12/31/23, 8/29/24
    • Reviewed: entries include 2/2010; 1/2014; 3/2016; and others through 7/22/25
    Denial Risk

    Denial risk for missing diagnosis or prior-regimen documentation

    Requests that do not document a diagnosis of T-ALL or T-LBL, or that do not document failure to respond to or relapse after at least two chemotherapy regimens, may be denied.

    • Missing documented diagnosis of T-ALL or T-LBL
    • Missing documentation of failure to respond to, or relapse following, ≥2 chemotherapy regimens
    Denial Risk

    Risk if administrative or criteria documentation is not present

    Absence of documented policy criteria changes or other administrative requirements in the cited sections may increase risk of denial if other parts of the policy are not met; consult the policy history and MA UM approvals as applicable.

    Services must not be primarily for the convenience of the Member or the Member's Health Care Provider.
    Level of serviceServices must represent the most appropriate source or level of service that can safely be provided to the Member.

    LOB carve out, Medicaid business segment, and generic drug language were added to the policy.

    2022-09-16Revision

    Medicaid PARP statement was added to the policy criteria.

    2015-03-24Revision

    Formatting changes and authorization duration updated.

    2012-02-01Revision

    Criteria revised in February 2012.

    2008-10-08Creation

    Policy devised on 2008-10-08.